Evidence map›Paper›PMID 25852282›Full record

ArticleWorld journal of gastroenterology2015

Methylation of IRAK3 is a novel prognostic marker in hepatocellular carcinoma.

Chih-Chi Kuo, Yu-Lueng Shih, Her-Young Su, Ming-De Yan, Chung-Bao Hsieh, Chin-Yu Liu, Wei-Ting Huang, Mu-Hsien Yu, Ya-Wen Lin

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Chih-Chi KuoChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Yu-Lueng ShihChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Her-Young SuChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Ming-De YanChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Chung-Bao HsiehChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Chin-Yu LiuChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Wei-Ting HuangChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Mu-Hsien YuChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Ya-Wen LinChih-Chi Kuo, Ya-Wen Lin, Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Tri-Service General Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo examine the methylation levels of interleukin-1 receptor-associated kinase 3 (IRAK3) and GLOXD1 and their potential clinical applications in hepatocellular carcinoma (HCC).

methodsmRNA expression and promoter methylation of IRAK3 and GLOXD1 in HCC cells were analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and methylation-specific PCR (MSP), respectively. Using pyrosequencing results, we further established a quantitative MSP (Q-MSP) system for the evaluation of IRAK3 and GLOXD1 methylation in 29 normal controls and 160 paired HCC tissues and their adjacent nontumor tissues. We also calculated Kaplan-Meier survival curves to determine the applications of gene methylation in the prognosis of HCC.

resultsIRAK3 and GLOXD1 expression was partially restored in several HCC cell lines after treatment with 5-aza-2'-deoxycytidine (DNA methyltransferase inhibitor; 5DAC). A partial decrease in the methylated band was also observed in the HCC cell lines after 5DAC treatment. Using GLOXD1 as an example, we found a significant correlation between the data obtained from the methylation array and from pyrosequencing. The methylation frequency of IRAK3 and GLOXD1 in HCC tissues was 46.9% and 63.8%, respectively. Methylation of IRAK3 was statistically associated with tumor stage. Moreover, HCC patients with IRAK3 methylation had a trend toward poor 3-year disease-free survival (P < 0.05).

conclusionIRAK3 and GLOXD1 were frequently methylated in HCC tissues compared to normal controls and nontumor tissues. IRAK3 methylation was associated with tumor stage and poor prognosis of patients. These data suggest that IRAK3 methylation is a novel prognostic marker in HCC.

Indexed as

DNA MethylationAdultAgedBase SequenceBiomarkers, TumorCarcinoma, HepatocellularFemaleGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHep G2 CellsHumansInterleukin-1 Receptor-Associated KinasesKaplan-Meier EstimateLiver NeoplasmsMaleMiddle AgedBiomarkers, TumorInterleukin-1 Receptor-Associated KinasesIRAK3 protein, humanRNA, MessengerDNA methylation biomarkerGLOXD1Hepatocellular carcinomaIRAK3PyrosequencingQuantitative methylation-specific polymerase chain reaction

Identifiers

PMID25852282
PMCPMC4385544
OpenAlexW2316685535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.